We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Technology 0.03%
3 Communication Services 0.01%
4 Consumer Discretionary 0.01%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
Edwards Lifesciences
EW
$53B
$66.9M 1.41%
739,234
-100,217
-12% -$8.4M
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.59B
$66.2M 1.39%
1,982,775
-397,225
-17% -$9.87M
UNH icon
28
UnitedHealth
UNH
$361B
$62M 1.3%
149,127
+924
+0.6% +$342K
DXCM icon
29
DexCom
DXCM
$33.9B
$55.4M 1.17%
822,489
+33,723
+4% +$2.25M
CLDX icon
30
Celldex Therapeutics
CLDX
$3.29B
$44.7M 0.94%
1,200,000
– –
AVLN
31
Avalyn Pharma
AVLN
$1.72B
$44.4M 0.94%
+1,350,000
New +$39M
DMRA
32
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.91B
$42.1M 0.89%
1,618,846
-679,154
-30% -$16.4M
IRON icon
33
Disc Medicine
IRON
$3.03B
$41M 0.86%
560,000
+100,686
+22% +$6.92M
TMO icon
34
Thermo Fisher Scientific
TMO
$219B
$40M 0.84%
79,816
+15,404
+24% +$7.39M
BSX icon
35
Boston Scientific
BSX
$75.6B
$37.9M 0.8%
887,650
-579,244
-39% -$31.5M
LLY icon
36
Eli Lilly
LLY
$1.05T
$35.8M 0.75%
29,882
-4,050
-12% -$4.14M
CGON icon
37
CG Oncology
CGON
$6.65B
$35.1M 0.74%
+493,596
New +$32.3M
IDXX icon
38
Idexx Laboratories
IDXX
$43.6B
$32.5M 0.68%
61,780
-27,351
-31% -$15.3M
RMD icon
39
ResMed
RMD
$32.6B
$28.9M 0.61%
148,195
-11,151
-7% -$2.31M
KRYS icon
40
Krystal Biotech
KRYS
$9.78B
$28.8M 0.61%
77,530
-404,255
-84% -$121M
GLUE icon
41
Monte Rosa Therapeutics
GLUE
$1.34B
$28.8M 0.61%
1,190,000
-60,000
-5% -$1.13M
DHR icon
42
Danaher
DHR
$143B
$27.4M 0.58%
143,844
-58,320
-29% -$10.6M
JNJ icon
43
Johnson & Johnson
JNJ
$630B
$26.2M 0.55%
103,280
-15,822
-13% -$3.69M
SPTX
44
Seaport Therapeutics
SPTX
$1.29B
$23.9M 0.5%
+1,100,000
New +$19.4M
PVLA
45
Palvella Therapeutics
PVLA
$2.23B
$23.7M 0.5%
+155,000
New +$18.8M
ALGN icon
46
Align Technology
ALGN
$12.9B
$23.6M 0.5%
139,680
– –
ANNX icon
47
Annexon
ANNX
$873M
$23.4M 0.49%
4,100,016
-1,057,274
-21% -$5.84M
HUM icon
48
Humana
HUM
$46.7B
$23.2M 0.49%
58,398
-6,100
-9% -$1.74M
ELV icon
49
Elevance Health
ELV
$87.2B
$21.8M 0.46%
56,449
+3,931
+7% +$1.46M
TNGX icon
50
Tango Therapeutics
TNGX
$4.26B
$21.7M 0.46%
694,182
-1,705,818
-71% -$42.2M
1
2
3 4 5

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.